Stockscreener 앱 받기
0.8575
0.06%
0.0005
시간 외 거래:
.83
-0.0275
-3.21%
전일 마감가:
$0.857
열려 있는:
$0.843
하루 거래량:
60,874
Relative Volume:
0.39
시가총액:
$48.41M
수익:
-
순이익/손실:
$-131.52M
주가수익비율:
-0.4817
EPS:
-1.78
순현금흐름:
$-107.56M
1주 성능:
+3.53%
1개월 성능:
+1.79%
6개월 성능:
-15.10%
1년 성능:
-84.24%
1일 변동 폭
$0.8325
$0.884
1주일 범위
$0.82
$0.91
52주 변동 폭
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
PRLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.8575 | 47.98M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
Will Prelude Therapeutics Incorporated bounce back from current supportCapital Growth Summary Over Five Years - Newser
Tick level data insight on Prelude Therapeutics Incorporated volatilityFree Low Volatility Stable Growth Picks - Newser
Can machine learning forecast Prelude Therapeutics Incorporated recoveryLong Term Stock Planner with Safety Checks - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionTen-Year Sector Performance and Summary Analysis - Newser
Is it time to cut losses on Prelude Therapeutics IncorporatedShort-Term Price Breakout Signal Analysis - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyFree Real Time Trade Opportunity Alerts - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryFree Weekly Growth Stock Entry Point Alerts - Newser
Using data filters to optimize entry into Prelude Therapeutics IncorporatedPredictive Analytics for Equity Growth Potential - Newser
Will Prelude Therapeutics Incorporated stock go up soonFree Weekly Hot Picks With Buy Confidence - Newser
Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Monday - Defense World
Published on: 2025-08-08 23:30:09 - Newser
Published on: 2025-08-08 17:57:29 - Newser
Prelude Therapeutics Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
Prelude Therapeutics Incorporated’s volatility index tracking explainedPattern Recognition Tool for ROI Investors - Newser
Has Prelude Therapeutics Incorporated found a price floorLong-Term Investment Strategy Summary Guide - Newser
Using fundamentals and technicals on Prelude Therapeutics IncorporatedTrend Following Ideas with Volume Confirmation - Newser
What recovery options are there for Prelude Therapeutics IncorporatedFree Swing Trade Entry With Volume Triggers - Newser
Using data models to predict Prelude Therapeutics Incorporated stock movementFree ROI Boosting Trade Opportunity Calendar - Newser
How to build a dashboard for Prelude Therapeutics Incorporated stockDay Trading Plan with Entry Risk Management - Newser
Is Prelude Therapeutics Incorporated stock entering bullish territoryPre-Market Stock Movement Summary and Review - Newser
Published on: 2025-08-04 06:59:59 - Newser
What institutional investors are buying Prelude Therapeutics Incorporated stockFree Predictions - Jammu Links News
Published on: 2025-08-04 00:18:44 - Newser
What analysts say about Prelude Therapeutics Incorporated stockGet ahead with breakthrough trading ideas - Jammu Links News
How volatile is Prelude Therapeutics Incorporated stock compared to the marketCapitalize on momentum stocks early - Jammu Links News
What are the technical indicators suggesting about Prelude Therapeutics IncorporatedMarket-leading growth rates - Jammu Links News
Does Prelude Therapeutics Incorporated qualify in momentum factor screeningBuy Strategy Tracker with Growth Indicators - Newser
Prelude Therapeutics Incorporated stock trendline breakdownFree Sector Based Breakout Stock Forecast - Newser
When is Prelude Therapeutics Incorporated stock expected to show significant growthNavigate market shifts with confidence - Jammu Links News
Should I hold or sell Prelude Therapeutics Incorporated stock in 2025Accelerated earnings growth - Jammu Links News
What are analysts’ price targets for Prelude Therapeutics Incorporated in the next 12 monthsAchieve rapid capital gains with smart investing - Jammu Links News
What is the dividend policy of Prelude Therapeutics Incorporated stockTriple-digit return opportunities - Jammu Links News
What are Prelude Therapeutics Incorporated company’s key revenue driversGet alerts on high-potential market moves - Jammu Links News
How does Prelude Therapeutics Incorporated compare to its industry peersExplosive market performance - Jammu Links News
Is it the right time to buy Prelude Therapeutics Incorporated stockUnmatched profit potential - Jammu Links News
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):